Company intelligence / Profile preview
ReAlta Life Sciences
- Ownership
- Private
- Employees
- ~20
- Development stage
- Phase 2
Overview
ReAlta's lead candidate RLS-0071 (pegtarazimod) has demonstrated an excellent safety profile and confirmed target engagement in First-in-Human Phase 1 clinical trials. The company is currently conducting Phase 2 clinical trials for RLS-0071 in newborns with hypoxic ischemic encephalopathy (HIE) and hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease (COPD). RLS-0071 has received Orphan Drug Designation and Fast Track Designation from the FDA for HIE and acute graft-versus-host disease (aGVHD) treatment.[4][5][7]
- Therapeutic areas
- HematologyPulmonologyNeurologyImmunology
- Modalities
- Engineered peptides
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on ReAlta Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReAlta Life Sciences.